PDS reports updated data from the IMMUNOCERV Phase 2 clinical trial

PDS Biotechnology announced that updated data from the IMMUNOCERV Phase 2 clinical trial evaluating Versamune HPV, formerly PDS0101, with chemoradiation to treat locally advanced cervical cancer were presented at the American Society for Radiation Oncology, or ASTRO, Annual Meeting 2024 in an oral presentation by Adam Grippin, of The University of Texas MD Anderson Cancer Center. The abstract was granted Basic/Translational Science Award from the ASTRO Annual Meeting Steering Committee.” The IMMUNOCERV Phase 2 clinical trial evaluated the efficacy, safety and tolerability of Versamune HPV in combination with standard-of-care chemoradiotherapy for the treatment of locally advanced cervical cancer. The investigator-initiated study enrolled 17 newly diagnosed high-risk patients with large tumors of at least 5 cm in size. Highlights from the presentation include: All patients received at least 2 doses of Versamune(R) HPV; Median follow-up was 19 months, 36-month overall survival rate was 84.4%, and 100% for the eight patients who received all five doses of Versamune HPV. Historical published data show 36-month OS rate with chemoradiation in this population of approximately 64%.